Home » Experts » Dr Dr Azra Raza
Expert Profile
Dr Azra Raza

Dr Azra Raza

Professor of Medicine,
Rush Cancer Institute,
Chicago

Dr Raza is Professor of Medicine and Director of the Pre-leukemia and Leukemia Program at Rush Cancer Institute (RCI) and the Rush-Presbyterian-St. Luke's Medical Center in Chicago. Dr.Raza completed her medical education in Karachi, Pakistan and her training in Internal Medicine at Georgrtown/VA Medical Center in Washington D.C. She finished her fellowship in Medical Oncology at Roswell Park Cancer Institute in Buffalo, New York, and stayed on from 1980 to 1989, to become Head of the Section of Cell Biology. She started her work investigating the cellular dynamics of the bone marrows in patients with acute myeloid leukemia and myelodysplastic syndromes at that institution and has been continuously funded by the National Cancer Institute (NCI) since 1984. She moved briefly to Cincinnati, and then to Chicago in 1992, where she has successfully established the single most clinically active and well-funded basic research program in the study of Myelodysplastic syndromes. Dr. Raza and her husband, Dr. Harvey Preisler are co-Principal Investigators on a ten million dollars five year program project grant from the NCI, in addition to being PI and/or co-PI on seven other grants. Dr. Raza has authored approximately 180 full length papers, 400 abstracts, and has been an invited speaker at almost every major University in the U.S., as well as National, and International meetings in the last decade. She is the Director of an exceptionally productive basic research lab with approximately 50 individuals including more than twenty outstanding PhDs and MDs. Dr. Raza sees more MDS patients as a single physician in a year than most cancer centers, totaling 200 to 250 cases a year. The critical aspect of the MDS program at Rush is that every patient is encouraged to participate in the ongoing clinical trials and companion biological studies so that a better understanding of biology of this disease can be achieved, and translated into improved therapies for the patients. Thepride of the program continues to be carefully conducted clinical trials resulting from novel biological insights.

 

................... Advertisement ...................

................... Advertisement ...................

 

FAQ

ASK OUR EXPERTS

Using 0 of 1024 Possible characters
Choose Topic

................... Advertisement ...................

-------------------------------- Advertisement -----------------------------------